OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	1263
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC	770
Retraction Note: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway	725
Retraction Note: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression	666
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	528
Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner	489
Editorial expression of concern: Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma	471
Retraction Note: CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p	452
Retraction Note: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway	447
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	432
Contract to kill: GNAS mutation	418
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications	385
Minimally invasive approaches for the early detection of endometrial cancer	362
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome	341
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer	310
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer	272
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy	252
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	249
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	243
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors	242
Radioresistance in rectal cancer: can nanoparticles turn the tide?	240
Retraction Note to: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis	240
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance	234
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	233
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes	219

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	216
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation	201
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	195
LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM	185
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	181
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial	176
Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC	168
Extracellular vesicles in tumor immunity: mechanisms and novel insights	165
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2	161
Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis	159
Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing	156
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	155
Understanding gold nanoparticles and their attributes in ovarian cancer therapy	153
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer	152
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial	147
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis	146
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	142
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?	142
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies	140
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	138
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	137
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	131
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	131
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	130
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	130
Unraveling the key role of chromatin structure in cancer development through epigenetic landscape characterization of oral cancer	127
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	126
LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer	125
Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies	125
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets	124
Novel humanized monoclonal antibodies against ROR1 for cancer therapy	123
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer	121
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	121
A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology	119
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	118
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	115
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	113
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication	113
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6	111
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma	111
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	110
A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer	106
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial	105
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives	105
Correction: Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	104
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib	103
Correction to: Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA	102
Correction: Nac1 promotes stemness and regulates myeloid‑derived cell status in triple‑negative breast cancer	102
Correction to: LMTK3 inhibition affects microtubule Stability	102
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy	102

Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	101
Correction to: Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription	100
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance	98
Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer	98
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	95
Correction: Reprogramming anchorage dependency by adherent‑to‑suspension transition promotes metastatic dissemination	95
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	95
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	94
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy	92
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	91
NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer	91
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application	90
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	90
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	89